ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1647809
This article is part of the Research TopicAutoantibodies in Cancer: Diagnostic, Prognostic, and Therapeutic PotentialView all 5 articles
Anti-OLA1 autoantibody is a potential early diagnostic marker for hepatocellular carcinoma
Provisionally accepted
- Zhengzhou University, Zhengzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background Early detection of hepatocellular carcinoma (HCC) enhances survival outcomes. Tumor-associated autoantibodies demonstrate early emergence during carcinogenesis, offering potential as non-invasive diagnostic biomarkers. This multicenter study aims to evaluate the diagnostic value of anti-OLA1 autoantibody in HCC. Methods Protein microarray was used to screen for autoantibodies in AFP - negative patients with HCC (ANHCC) and normal controls (NC) during the discovery stage. In the validation stage, 413 HCC patients and 655 control from three centers were recruited to evaluate anti-OLA1 autoantibody performance using enzyme-linked immunosorbent assay. Receiver Operating Characteristic (ROC) curve analysis and area under the curve (AUC) were used to assess its diagnostic value. Anti-OLA1 autoantibody was combined with liver function parameters in a logistic regression model to improve HCC diagnosis. Finally, OLA1 expression, immune infiltration, and prognostic impact were analyzed using public databases. Results Anti-OLA1 autoantibody was identified by protein microarray with an AUC of 0.75 for distinguishing ANHCC from NC. Multi-center validation confirmed these results, showing AUCs from 0.607 to 0.713 and sensitivity from 18.8% to 35.2%. Incorporating liver function parameters significantly improved diagnostic efficiency, with a net reclassification index of 1.04 and an integrated discrimination index of 0.46 in Zhengzhou, validated by an AUC of 0.93 in Nanchang. Public database analysis revealed OLA1 overexpression in HCC tissues correlates with increased immune cell infiltration and predicts poor early prognosis (P<0.05). Conclusion Anti-OLA1 autoantibody shows promise as a serological HCC biomarker, with diagnostic performance significantly enhanced through combination with routine liver function parameters.
Keywords: HCC, Autoantibody, diagnostic, OLA1, Plasma
Received: 16 Jun 2025; Accepted: 16 Oct 2025.
Copyright: © 2025 Xiong, Duan, Dai, Wang, Ye, Shi and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Keyan Wang, wangkeyan0902@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.